{"entity":{"id":"ak117","kind":"drug","name":"AK117","aka":[],"tldr":"AK117 is an experimental investigational agent whose form is not stated in the registry from Akeso in phase 3 trials for head and neck squamous cell carcinoma, colorectal cancer and non-small-cell lung cancer, with its target not yet stated publicly.","summary":"AK117 is an investigational agent whose form is not stated in the registry developed by Akeso. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06601335 (A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)), in head and neck squamous cell carcinoma, colorectal cancer, non-small-cell lung cancer, acute myeloid leukaemia and triple-negative breast cancer. The largest, NCT06601335, plans to enrol 510 participants with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of AK117","url":"https://clinicaltrials.gov/search?intr=AK117"},{"label":"NCI Drug Dictionary: ligufalimab","url":"https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ligufalimab"},{"label":"ClinicalTrials.gov NCT04980885","url":"https://clinicaltrials.gov/study/NCT04980885"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck","colorectal","nsclc","aml","tnbc","sclc"],"sections":[],"technologies":[],"targets":["cd47"],"drugs":[],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06601335","nct07245446","nct05382442","nct05229497","nct05227664","nct04980885"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["AK117 is ligufalimab, a humanised IgG4 monoclonal antibody against CD47 that blocks the CD47 to SIRP-alpha signal tumour cells use to avoid being eaten by macrophages (NCI Drug Dictionary; ClinicalTrials.gov NCT04980885 is titled \"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia\")."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody (AK117 is ligufalimab; INN stem -mab; form not stated in the registry record)","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ak117/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}],"trial":[{"id":"nct06601335","kind":"trial","name":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","route":"/trials/nct06601335/"},{"id":"nct05229497","kind":"trial","name":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","route":"/trials/nct05229497/"},{"id":"nct05382442","kind":"trial","name":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","route":"/trials/nct05382442/"},{"id":"nct05227664","kind":"trial","name":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","route":"/trials/nct05227664/"},{"id":"nct07245446","kind":"trial","name":"A Study of Ivonescimab in First-Line ES-SCLC","route":"/trials/nct07245446/"},{"id":"nct04980885","kind":"trial","name":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","route":"/trials/nct04980885/"}]}}